OLD National Bancorp IN Trims Stock Position in Humana Inc. (NYSE:HUM)

OLD National Bancorp IN cut its position in shares of Humana Inc. (NYSE:HUM) by 20.5% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,568 shares of the insurance provider’s stock after selling 663 shares during the period. OLD National Bancorp IN’s holdings in Humana were worth $960,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of HUM. Norges Bank purchased a new position in Humana during the fourth quarter worth about $676,800,000. Sanders Capital LLC purchased a new stake in Humana during the 4th quarter worth approximately $489,300,000. Ontario Teachers Pension Plan Board increased its stake in Humana by 11,647.2% during the 1st quarter. Ontario Teachers Pension Plan Board now owns 1,059,478 shares of the insurance provider’s stock worth $367,342,000 after buying an additional 1,050,459 shares during the period. Putnam Investments LLC increased its stake in Humana by 550.3% during the 4th quarter. Putnam Investments LLC now owns 875,489 shares of the insurance provider’s stock worth $400,808,000 after buying an additional 740,858 shares during the period. Finally, Steadfast Capital Management LP purchased a new stake in Humana during the 1st quarter worth approximately $158,813,000. 92.38% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. Deutsche Bank Aktiengesellschaft upped their target price on shares of Humana from $341.00 to $349.00 and gave the stock a “hold” rating in a research note on Friday, August 2nd. TD Cowen boosted their price target on shares of Humana from $396.00 to $407.00 and gave the stock a “buy” rating in a report on Wednesday, July 24th. Jefferies Financial Group lowered their price target on shares of Humana from $411.00 to $381.00 and set a “buy” rating for the company in a report on Monday, April 22nd. Cantor Fitzgerald reiterated a “neutral” rating and set a $360.00 price target on shares of Humana in a report on Tuesday, July 23rd. Finally, Truist Financial boosted their price target on shares of Humana from $355.00 to $400.00 and gave the stock a “hold” rating in a report on Monday, July 15th. Thirteen equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Humana has a consensus rating of “Hold” and a consensus price target of $403.55.

Humana Trading Up 0.2 %

HUM stock traded up $0.63 during midday trading on Friday, hitting $350.95. The stock had a trading volume of 628,053 shares, compared to its average volume of 1,722,164. Humana Inc. has a 12-month low of $298.61 and a 12-month high of $530.54. The firm has a market cap of $42.29 billion, a PE ratio of 21.85, a price-to-earnings-growth ratio of 2.09 and a beta of 0.51. The company’s 50-day moving average price is $368.08 and its 200 day moving average price is $347.01. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.66 and a quick ratio of 1.67.

Humana (NYSE:HUM) last released its earnings results on Wednesday, July 31st. The insurance provider reported $6.96 EPS for the quarter, beating the consensus estimate of $5.89 by $1.07. Humana had a return on equity of 16.12% and a net margin of 1.53%. The firm had revenue of $29.54 billion during the quarter, compared to analyst estimates of $28.52 billion. During the same period in the prior year, the firm posted $8.94 earnings per share. The business’s quarterly revenue was up 10.4% compared to the same quarter last year. On average, equities research analysts predict that Humana Inc. will post 16.14 earnings per share for the current fiscal year.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.